No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1286.0x · 10Y median 948.3x · 100th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 28
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:52.693Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Nautilus Biotechnolgy, Inc. (NAUT) stock was $1.92 as of Oct 6, 2026, 12:25 PM EDT, up 2.67% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +111.1% · 3-year avg -15.3%/yr · 5-year avg -20.6%/yr
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Biotechnology · Seattle, WA
Next Earnings Date
Oct 26, 2026
20 days away
EPS Estimate
-0.14
Revenue Est.
$206250.00
Last Quarter Results
EPS
$-0.11
vs Estimate
$-0.14
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NAUT | $244.33M | $1.92 | +2.67% | +111.12% | -20.56% | N/A | N/A |
| 2IVVD | $244.52M | $0.83 | -1.10% | -27.54% | -51.69% | N/A | vs NAUT |
| 3LFCR | $243.62M | $6.50 | -0.38% | -6.56% | -7.12% | -6.99% | vs NAUT |
| 4QTTB | $245.85M | $8.26 | -1.31% | +301.66% | -41.51% | N/A | vs NAUT |
| 5GLSI | $242.34M | $16.51 | -2.37% | +54.67% | -14.84% | N/A | vs NAUT |
| 6GALT | $241.69M | $3.67 | -1.61% | -13.80% | +0.60% | +13.41% | vs NAUT |
forward FY estimate
N/A
$190000.00
vs Estimate
$100000.00
Consensus Rating
Based on 3 analysts
Average Price Target
$3.83
+99.7% upside
Low
$3.50
Current
$1.92
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.14 | $-0.14 | 2 |
| Quarter ending Dec 2026 | $-0.15 | $-0.14 | $-0.13 | 2 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.12 | 1 |
| Quarter ending Jun 2027 | $-0.14 | $-0.13 | $-0.13 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.70 | $-0.51 | $-0.40 | 3 |
| FY 2027 | $-0.71 | $-0.52 | $-0.41 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $202453.00 | $206250.00 | $217638.00 | 2 |
| Quarter ending Dec 2026 | $203680.00 | $207500.00 | $218957.00 | 2 |
| Quarter ending Mar 2027 | $331288.00 | $337500.00 | $356134.00 | 1 |
| Quarter ending Jun 2027 | $650306.00 | $662500.00 | $699079.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $448366.00 | $536250.00 | $684970.00 | 3 |
| FY 2027 | $4.31M | $5.16M | $6.59M | 3 |
